Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MitoQ and exercise: a new hope for Long-COVID recovery in older veterans?

NCT ID NCT05373043

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study is testing whether a dietary supplement called MitoQ, combined with exercise rehabilitation, can improve blood vessel function in older adults (50+) suffering from long-COVID. The trial will enroll 300 participants, including both long-COVID patients and those who have recovered from COVID-19. The goal is to see if this approach can reduce the long-term health consequences of the infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mitoquinone (MitoQ) dietary supplement
What this could lead to
If successful, this could point toward a practical, low-cost combination of a supplement and exercise to help older adults recover from long-COVID.
What could go wrong
This is a relatively small, early-stage study focused on blood vessel function, not on curing long-COVID. The supplement may not provide meaningful symptom relief, and results may not apply to younger or healthier people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis * Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis * Ability to sign informed consent Exclusion Criteria: * BMI \>45 kg/m2 * Unstable (\<6 months) or severe coronary artery disease (CAD-RADS score = 4A), peripheral artery disease (Ankle Brachial Index \<0.40), cerebrovascular disease (identified by previous stroke in last 12 months), severe COPD (=Stage III), uncontrolled hypertension (\>160/100 mmHg), chronic kidney disease requiring dialysis, severe renal insufficiency (creatinine clearance \<30 by the Cockcroft-Gault formula), Alzheimer's disease, dementia * Orthopedic limitations that would prohibit exercise * Current smokers and individuals that stopped smoking in the last 10 years * Already taking Mito-Q or unwilling to cease dietary supplements for participation * Any other condition or event considered exclusionary by the PIs or a physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    RECRUITING

    Salt Lake City, Utah, 84148-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.